Mind Medicine (MindMed) Company Description

Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders.

The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder.

Mind Medicine (MindMed) Inc. is headquartered in New York, New York.

Mind Medicine (MindMed) Inc.

Country	Canada
Industry	Pharmaceutical Preparations
Employees	74
CEO	Robert Barrow

Contact Details

Address: One World Trade Center New York, British Columbia 10007 United States
Phone	212 220 6633
Website	mindmed.co

Stock Details

Ticker Symbol	MMQ
Exchange	Frankfurt Stock Exchange
Fiscal Year	January - December
Reporting Currency	USD
SIC Code	2834

Key Executives

Name	Position
Robert Barrow	Chief Executive Officer
Brandi Roberts	Chief Financial Officer
Peter Mack	Chief Operating Officer